EGFR and non-small cell lung carcinoma: Dacomitinib has shown superiority over gefitinib as first line treatment in NSCLC patients with Exon 19 or Leu858Arg mutation of EGFR, regarding PFS in the multicenter ARCHER 1050 trial [35].